000168703 001__ 168703
000168703 005__ 20240229133613.0
000168703 0247_ $$2doi$$a10.1007/s00066-021-01785-2
000168703 0247_ $$2pmid$$apmid:33938966
000168703 0247_ $$2ISSN$$a0179-7158
000168703 0247_ $$2ISSN$$a1439-099X
000168703 037__ $$aDKFZ-2021-01011
000168703 041__ $$aEnglish
000168703 082__ $$a610
000168703 1001_ $$0P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aStoian, Raluca$$b0$$udkfz
000168703 245__ $$aIntraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis.
000168703 260__ $$aHeidelberg$$bSpringer Medizin$$c2021
000168703 3367_ $$2DRIVER$$aarticle
000168703 3367_ $$2DataCite$$aOutput Types/Journal article
000168703 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634304342_1830
000168703 3367_ $$2BibTeX$$aARTICLE
000168703 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168703 3367_ $$00$$2EndNote$$aJournal Article
000168703 500__ $$a 2021 Sep;197(9):812-819
000168703 520__ $$aThere are currently no data from randomized controlled trials on the use of intraoperative radiotherapy (IORT) as a tumor bed boost as part of a breast-conservation approach for breast cancer. This study retrospectively reviewed the safety and efficacy of IORT as a boost treatment at a tertiary cancer center.From 2015 to 2019, patients underwent breast-conserving surgery with axillary lymph node staging and a single dose of 20 Gy IORT with 50-kV photons, followed by whole-breast irradiation (WBI) and adjuvant systemic therapy (if applicable). Patients were followed for assessment of acute and late toxicities (using the Common Terminology Criteria for Adverse Events version 5.0) at 3-6-month intervals. Outcomes included ipsilateral (IBTR) and contralateral breast progression-free survival (CBE), distant metastasis-free survival (DMFS), and overall survival (OS).Median follow-up for the 214 patients was 28 (range 2-59) months. Most patients had T1 disease (n = 124) and were clinically node negative. Only few patients had high-grade and/or triple-negative disease. The vast majority of patients underwent sentinel node biopsy, and 32 (15%) required re-resection for initially positive margins. Finally, all tumor bed margins were clear. Nine (4.2%) and 48 (22.4%) patients underwent neoadjuvant and adjuvant chemotherapy, respectively. WBI was predominantly performed as conventionally fractionated WBI (n = 187, 87.4%), and the median time from BCS to WBI was 54.5 days. IORT was delivered with a single dose of 20 Gy. The median WBI dose was 50 Gy (range 29.4-50.4 Gy). No patients experienced grade 4 events; acute grade 3 toxicities were limited to 17 (8%) cases of radiation dermatitis. Postoperative toxicities were mild. After WBI only one case of late grade ≥ 2 events was reported. There were two recurrences in the tumor bed and one contralateral breast event.This investigation provides additional preliminary data supporting the using of IORT in the boost setting and corroborates the existing literature. These encouraging results should be prospectively validated by the eventual publication of randomized studies such as TARGIT‑B.
000168703 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168703 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168703 650_7 $$2Other$$aAdjuvant radiation therapy
000168703 650_7 $$2Other$$aBoost
000168703 650_7 $$2Other$$aBreast-conservation therapy
000168703 650_7 $$2Other$$aEarly breast cancer
000168703 650_7 $$2Other$$aIntraoperative radiotherapy
000168703 7001_ $$aErbes, Thalia$$b1
000168703 7001_ $$0P:(DE-HGF)0$$aZamboglou, Constantinos$$b2
000168703 7001_ $$0P:(DE-HGF)0$$aScholber, Jutta$$b3
000168703 7001_ $$0P:(DE-HGF)0$$aGainey, Mark$$b4
000168703 7001_ $$0P:(DE-HGF)0$$aSachpazidis, Ilias$$b5
000168703 7001_ $$0P:(DE-HGF)0$$aHaehl, Erik$$b6
000168703 7001_ $$0P:(DE-HGF)0$$aSpohn, Simon K B$$b7
000168703 7001_ $$aVerma, Vivek$$b8
000168703 7001_ $$aKrug, David$$b9
000168703 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b10$$udkfz
000168703 7001_ $$aJuhasz-Böss, Ingolf$$b11
000168703 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b12
000168703 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils H$$b13$$udkfz
000168703 7001_ $$0P:(DE-HGF)0$$aSprave, Tanja$$b14
000168703 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-021-01785-2$$n9$$p812-819$$tStrahlentherapie und Onkologie$$v197$$x1439-099X$$y2021
000168703 909CO $$ooai:inrepo02.dkfz.de:168703$$pVDB
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168703 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000168703 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168703 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000168703 9141_ $$y2021
000168703 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-26$$wger
000168703 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000168703 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2019$$d2021-01-26
000168703 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-26
000168703 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000168703 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x1
000168703 980__ $$ajournal
000168703 980__ $$aVDB
000168703 980__ $$aI:(DE-He78)FR01-20160331
000168703 980__ $$aI:(DE-He78)E055-20160331
000168703 980__ $$aUNRESTRICTED